Company Focus
Icon
Latest Icon News
Biotechnology
Chinese biotech dominance and opportunities for Western companies to stay competitive have been highlighted in surveys released by clinical research organization ICON. 10 December 2025
Related News
Insights
Company Spotlight
A privately held biotechnology platform company based in the Boston, Massachusetts area. It operates as a partner-facing “ecosystem” business supporting biologics discovery and development across multiple modalities, and it also participates in company creation through its venture studio model.
Latest News & Features of interest to Icon
Biotechnology
Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated. 16 January 2026
Biotechnology
WuXi XDC has made a bid to buy fellow Chinese firm BioDlink, a fully integrated CDMO offering end-to-end biologics development and manufacturing services. 16 January 2026
Biotechnology
Italian non-profit organization Fondazione Telethon today announced the European Commission’s decision of January 9, to grant marketing authorization for Waskyra (etuvetidigene autotemcel), an ex vivo gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS), a rare and severe genetic immunodeficiency. 16 January 2026
Pharmaceutical
As many as four decisions under the US Food and Drug Administration’s (FDA) new fast-track program have been delayed, Reuters has reported. 16 January 2026
Biotechnology
Indian drug major Sun Pharmaceutical Industries yesterday announced that Unloxcyt (cosibelimab-ipdl) is now available in the USA for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. 16 January 2026
Pharmaceutical
DelveInsight says the US hemophagocytic lymphohistiocytosis (HLH) market was worth about $140 million in 2024, reflecting a small but high-need patient population and outcomes that remain challenging even with aggressive care. 16 January 2026
Pharmaceutical
Japanese drugmaker Tanabe Pharma said its oral candidate dersimelagon met the primary endpoint and showed a favorable safety profile in INSPIRE, a global Phase III trial in erythropoietic protoporphyria and X-linked protoporphyria, two ultra-rare disorders marked by painful reactions to light. 16 January 2026
Biotechnology
Japan’s Eisai has reached a license agreement with Nuvation Bio, a global oncology company focused on tackling some of the toughest challenges in cancer treatment, that significantly expands the long-term global footprint of Ibtrozi (taletrectinib) in the USA and Japan.. 16 January 2026
Pharmaceutical
iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models. 16 January 2026
Pharmaceutical
China’s National Medical Products Administration has approved two innovative medicines licensed to French pharma major Sanofi, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. 15 January 2026
Latest In Brief for Icon
Pharmaceutical
French pharma major Sanofi is preparing an offer to acquire the US biopharmaceutical firm Ocular Therapeutix, according to a report by French publication La Lettre. 16 January 2026
Latest Relevant Ones To Watch News
WuXi XDC has made a bid to buy fellow Chinese firm BioDlink, a fully integrated CDMO offering end-to-end biologics development and manufacturing services. 16 January 2026
15 January 2026
13 January 2026
8 January 2026
6 January 2026
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze